Edesa Biotech (EDSA) vs Nasus Pharma (NSRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Edesa Biotech (EDSA) has outperformed Nasus Pharma (NSRX) over the past year, gaining 17.6% versus a loss of 68.4%. Edesa Biotech is the larger company by market cap ($27.0 million vs $26.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | NSRX |
|---|---|---|
| Share price | $2.00 | $2.29 |
| Market cap | $27.02M | $26.82M |
| 1-day change | -8.05% | -10.20% |
| YTD return | +40.85% | -74.97% |
| 1-year return | +17.65% | -68.41% |
| 5-year return | -95.63% | — |
| EPS (TTM) | $-1.72 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.24B |
| Net income (latest FY) | $-7.19M | $-5.86M |
| Operating margin | — | -0.40% |
| Net margin | — | -0.47% |
| 52-week high | $20.32 | $9.50 |
| 52-week low | $0.72 | $1.98 |
| Distance from 52-week high | -90.16% | -75.89% |
| Analyst consensus | none | buy |
| Avg. price target upside | +716.50% | +758.95% |
| Average volume | 1.45M | 16.80K |
| Shares outstanding | 13.51M | 11.71M |
| Employees | 17 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed NSRX by 86.1 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Nasus Pharma
NSRX stock →Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
EDSA vs NSRX FAQ
Which is bigger, Edesa Biotech or Nasus Pharma?
Edesa Biotech (EDSA) is larger, with a market capitalization of $27.02M compared with $26.82M for Nasus Pharma (NSRX).
Which stock has performed better over the past year, EDSA or NSRX?
EDSA returned +17.65% over the past 12 months, compared with -68.41% for NSRX (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and Nasus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.